Sun 13 Sep 2026 International edition

Biochemistry & Metabolomics Unlocking Japan’s Deep-Time Secrets: Overlooked Fossils Reveal Potential New Mosasaur Species After Three Decades in Storage

Toxicology & Pharmacology Breaking the Vicious Cycle: ETH Zurich Researchers Unveil "Compound 10" as a Potential Breakthrough in Alzheimer’s Progression

Medical Devices & Lab Automation Mapping the Highway of Life: Researchers Unveil the World’s First Comprehensive Human Vagus Nerve Atlas

Microbiology & Infectious Diseases Nature’s Biochemical Race: How Accelerated Immune Maturation is Saving Amphibians from the Chytrid Crisis

Hematology & Blood Research Paradigm Shift in Hematology: Landmark Meta-Analysis Challenges Intensive Chemotherapy Norms for High-Risk Acute Promyelocytic Leukemia

Bio-Research & Life Sciences The Draining of the Asian Water Tower: How AI and Satellites Uncovered a Looming Hydrological Crisis

Bio-Research & Life Sciences Unlocking the 518-Million-Year-Old Genesis of Spider Fangs: A Paleontological Breakthrough

Biochemistry & Metabolomics The Invisible Crew: How Earth’s Resilient Microbes Could Survive in the Shadows of the Moon

Clinical Trials & Research Airway Therapeutics Secures $50M in Equity Financing to Advance Late-Stage Trials of Zelpultide Alfa for Bronchopulmonary Dysplasia in Preterm Infants

Precision Medicine Unlocking Personalized Cardiovascular Care: Oxford Researchers Introduce Revolutionary Statin Risk Calculator

Healthcare Quality & Safety Executive Overview: The Hidden Crisis of Dehydration Among Healthcare Workers

Medical Biotechnology Healing from Within: MIT Researchers Discover How a Common Amino Acid Powers Intestinal Regeneration

Archive

Tag: setback

AstraZeneca’s Phase III NSCLC Trial Setback: Re-Evaluating the PD-1 Bispecific Strategy in Advanced Oncology

Clinical Trials & Research

AstraZeneca’s Phase III NSCLC Trial Setback: Re-Evaluating the PD-1 Bispecific Strategy in Advanced Oncology

Executive Overview The landscape of immuno-oncology has long been defined by the pursuit of combination therapies and multi-targeted biologic agents...

23 Aug 2026